These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 19894779

  • 1. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
    Papaetis GS, Syrigos KN.
    BioDrugs; 2009; 23(6):377-89. PubMed ID: 19894779
    [Abstract] [Full Text] [Related]

  • 2. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
    Ayllon J, Beuselinck B, Morel A, Barrascout E, Medioni J, Scotte F, Oudard S.
    Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
    [Abstract] [Full Text] [Related]

  • 3. Sunitinib: from rational design to clinical efficacy.
    Chow LQ, Eckhardt SG.
    J Clin Oncol; 2007 Mar 01; 25(7):884-96. PubMed ID: 17327610
    [Abstract] [Full Text] [Related]

  • 4. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
    Adams VR, Leggas M.
    Clin Ther; 2007 Jul 01; 29(7):1338-53. PubMed ID: 17825686
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
    Zhou A, Zhang W, Chang C, Chen X, Zhong D, Qin Q, Lou D, Jiang H, Wang J.
    Cancer Chemother Pharmacol; 2013 Nov 01; 72(5):1043-53. PubMed ID: 24043137
    [Abstract] [Full Text] [Related]

  • 6. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.
    Am J Clin Oncol; 2010 Jun 01; 33(3):217-20. PubMed ID: 19745694
    [Abstract] [Full Text] [Related]

  • 7. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L.
    Expert Opin Pharmacother; 2012 Jun 01; 13(9):1323-36. PubMed ID: 22607009
    [Abstract] [Full Text] [Related]

  • 8. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A.
    Oncologist; 2007 Feb 01; 12(2):191-200. PubMed ID: 17296815
    [Abstract] [Full Text] [Related]

  • 9. Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
    Sulkes A.
    Isr Med Assoc J; 2010 Oct 01; 12(10):628-32. PubMed ID: 21090521
    [Abstract] [Full Text] [Related]

  • 10. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
    Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D.
    Mol Cancer Ther; 2006 Jul 01; 5(7):1774-82. PubMed ID: 16891463
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Sunitinib malate.
    Izzedine H, Buhaescu I, Rixe O, Deray G.
    Cancer Chemother Pharmacol; 2007 Aug 01; 60(3):357-64. PubMed ID: 17136543
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD.
    J Clin Oncol; 2008 Apr 10; 26(11):1810-6. PubMed ID: 18347007
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
    Valle JW, Faivre S, Hubner RA, Grande E, Raymond E.
    Cancer Treat Rev; 2014 Dec 10; 40(10):1230-8. PubMed ID: 25283354
    [Abstract] [Full Text] [Related]

  • 16. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS.
    J Clin Oncol; 2008 Jul 10; 26(20):3403-10. PubMed ID: 18612155
    [Abstract] [Full Text] [Related]

  • 17. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.
    Cabebe E, Wakelee H.
    Drugs Today (Barc); 2006 Jun 10; 42(6):387-98. PubMed ID: 16845442
    [Abstract] [Full Text] [Related]

  • 18. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
    Bai L, Yang JC, Ok JH, Mack PC, Kung HJ, Evans CP.
    Int J Cancer; 2012 Jun 01; 130(11):2693-702. PubMed ID: 21792888
    [Abstract] [Full Text] [Related]

  • 19. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK.
    Br J Dermatol; 2009 Nov 01; 161(5):1045-51. PubMed ID: 19558553
    [Abstract] [Full Text] [Related]

  • 20. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ, Hudes GR, Ginsberg MS, Baum MS, Harmon CS, Kim ST, Chen I, Redman BG.
    Am J Clin Oncol; 2010 Dec 01; 33(6):614-8. PubMed ID: 20142724
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.